Oral Supplement Containing Hydroxytyrosol and Punicalagin Improves Dyslipidemia in an Adult Population without Co-Adjuvant Treatment: A Randomized, Double-Blind, Controlled and Crossover Trial

Quirós Fernández, RebecaLópez Plaza, BriciaBermejo López, Laura MaríaPalma Milla, SamaraZangara, AndreaGómez Candela, Carmen2023-06-222023-06-222022-04-292072-664310.3390/nu14091879https://hdl.handle.net/20.500.14352/73406The present clinical trial was supported by the Euromed S.A. group through the HENUFOOD project (CEN-20101016) from the CENIT program of Economy and Competitiveness Ministry 481 of Spain (MINECO) and the University Hospital La Paz.Hydroxytyrosol (HT) and punicalagin (PC) exert cardioprotective and antiatherosclerotic effects. This study evaluated the effect of an oral supplement containing HT and PC (SAx) on dyslipidemia in an adult population. A randomized, double-blind, controlled, crossover trial was conducted over a 20-week period. SAx significantly reduced the plasma levels of triglycerides (TG) in subjects with hypertriglyceridemia (≥150 mg/dL) (from 200.67 ± 51.38 to 155.33 ± 42.44 mg/dL; p < 0.05), while no such effects were observed in these subjects after the placebo. SAx also significantly decreased the plasma levels of low-density lipoprotein cholesterol (LDL-C) in subjects with high plasma levels of LDL-C (≥160 mg/dL) (from 179.13 ± 16.18 to 162.93 ± 27.05 mg/dL; p < 0.01), while no such positive effect was observed with the placebo. In addition, the placebo significantly reduced the plasma levels of high-density lipoprotein cholesterol (HDL-C) in the total population (from 64.49 ± 12.65 to 62.55 ± 11.57 mg/dL; p < 0.05), while SAx significantly increased the plasma levels of HDL-C in subjects with low plasma levels of HDL-C (<50 mg/dL) (from 44.25 ± 3.99 to 48.00 ± 7.27 mg/dL; p < 0.05). In conclusion, the supplement containing HT and PC exerted antiatherosclerotic and cardio-protective effects by considerably improving dyslipidemia in an adult population, without co-adjuvant treatment or adverse effects.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/Oral Supplement Containing Hydroxytyrosol and Punicalagin Improves Dyslipidemia in an Adult Population without Co-Adjuvant Treatment: A Randomized, Double-Blind, Controlled and Crossover Trialjournal articlehttps://doi.org/10.3390/nu14091879https://www.mdpi.com/2072-6643/14/9/1879open access616.12-005Cardiovascular diseaseAtherosclerosisHydroxytyrosolPunicalaginDyslipidemiaTotal cholesterolLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolTriglyceridesQuímica orgánica (Química)MedicinaSistema cardiovascular2306 Química Orgánica32 Ciencias Médicas2411.03 Fisiología Cardiovascular